权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel MRI and 1H-MRS markers in Primary Progressive MS

原发性进展型多发性硬化症中的新型 MRI 和 1H-MRS 标记物

基本信息

批准号：
7345394
负责人：
Matilde INGLESE
金额：
$ 36.92万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-01-01 至 2009-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7345394
关键词：
Age Apoptosis Appendix Blood Blood Vessels Brain Brain Pathology Cerebrospinal Fluid Cerebrovascular Circulation Child Choline Clinical Clinical Trials Cognitive Creatine Data Deterioration Development Plans Diffuse Disease Disease Marker Disease Progression Face Failure Gender Gliosis Impairment Inflammation Injury Inositol Laboratories Lead Lesion Letters Literature Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Manuscripts Measures Metabolic Methods Metric Microscopic Minority Monitor Multiple Sclerosis Neurologic Neurons Neuropsychological Tests None or Not Applicable Numbers Oligodendroglia Outcome Measure Patients Performance Perfusion Phase Play Population Predisposition Primary Progressive Multiple Sclerosis Progress Reports Protons Publications Randomized Controlled Clinical Trials Rate Relapse Relapsing-Remitting Multiple Sclerosis Research Research Design Research Personnel Resources Role Safety Score Severities Techniques Testing Time Vertebrates Weight Woman brain tissue brain volume cohort disability human subject novel outcome forecast programs receptor repaired time use

项目摘要

four pages) Other Biographical Sketches (Not to exceed four pages for each - Seeinstructions) Resources 33 Research Plan. 33 Introduction to Revised Application (Not to exceed 3 pages) 33 Introduction to Supplemental Application (Not to exceed one page) N/A A. Specific Aims 36 B. Background and Significance 37 C. Preliminary Studies/Progress Report/ (Items A-D: not to exceed 25 pages*) 44 Phase I Progress Report (SBIR/STTR Phase II ONLY) * SBIR/STTR Phase I: Items A-D limited to 15 pages. D. Research Design and Methods 50 E. Human Subjects 58 Protection of Human Subjects (Required if Item 4 on the Face Page is marked "Yes") 58 Inclusion of Women (Required if Item 4 on the Face Page is marked "Yes") _58 Inclusion of Minorities (Required if Item 4 on the Face Page is marked "Yes") _58 Inclusion of Children (Required if Item 4 on the Face Page is marked "Yes") 58 Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked "Yes" and a Phase I, II, or III clinical trial is proposed F. Vertebrate Animals 60 G. Literature Cited 60 H. Consortium/Contractual Arrangements 66 I. Letters of Support (e.g., Consultants) 68 J. Product Development Plan (SBIR/STTR Phase II and Fast-Track ONLY) N/A Checklist. 69 Check if Appendix (Five collatedsets. Nopage numbering necessary for Appendix.) Appendix is Included Appendices NOT PERMITTED for Phase I SBIR/STTR unless specifically solicited.... Number of publications and manuscripts accepted for publication (notto exceed10) Other items (list): 1. Letter of support: Prof. John DeLuca, consultant PHS 398 (Rev. 05/01) Page. Form Page 3 Use /2-inch MARGINS. Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.

四页）其他个人简介（每份不超过四页-见说明）资源33 研究计划。33 修改后的申请简介（不超过3页）33 补充申请简介（不超过一页）N/A A.具体目标36 B。背景与意义37 C.初步研究/进度报告/（项目A-D：不超过25页 *）44 第I阶段进度报告（仅限SBIR/STTR第II阶段）* SBIR/STTR第I阶段：A-D项限制为15页。 D.研究设计与方法50 E.人类受试者58 人类受试者保护（如果正面页面上的第4项标记为“是”，则需要）58 纳入女性（如果正面页面上的项目4标记为“是”，则需要）_58 包括少数民族（如果首页上的项目4标记为“是”，则为必填项）_58 包括儿童（如果正面页面上的第4项标记为“是”，则需要）58 数据和安全性监测计划（如果正面页面上的第4项标记为“是”，则需要提供I、II或III期临床试验）建议试用 F.脊椎动物60 G.引用文献60 H.联营集团/合同安排 I.支持信（例如，顾问）68 J.产品开发计划（仅SBIR/STTR第二阶段和快速通道）N/A 清单。69 检查是否附录（五个整理集。附录所需的页码编号。）阑尾是包括附录不允许用于第I阶段SBIR/STTR，除非特别征求…… 出版物和被接受出版的手稿数量（不超过10份）其他项目（列表）： 1.支持信：John DeLuca教授，顾问 PHS 398（Rev. 05/01）第3页使用/2英寸边缘。在整个应用程序的底部连续编号页面。不要使用后缀，如3a，3b。